<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4382166</article-id><article-id pub-id-type="pmid">25830305</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0120649</article-id><article-id pub-id-type="publisher-id">PONE-D-14-48523</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Analyses of the Transcriptome and Metabolome Demonstrate That HIF1&#x003b1; Mediates Altered Tumor Metabolism in Clear Cell Renal Cell Carcinoma</article-title><alt-title alt-title-type="running-head">HIF1&#x003b1; Mediates Tumor Metabolism in Renal Cell Carcinoma</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Minton</surname><given-names>Denise R.</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Fu</surname><given-names>Leiping</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Qiuying</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Robinson</surname><given-names>Brian D.</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gross</surname><given-names>Steven S.</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nanus</surname><given-names>David M.</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gudas</surname><given-names>Lorraine J.</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref><xref ref-type="aff" rid="aff004"><sup>4</sup></xref><xref rid="cor001" ref-type="corresp">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label><addr-line>Department of Pharmacology, Weill Cornell Graduate School of Medical Sciences, New York, New York, United States of America</addr-line></aff><aff id="aff002"><label>2</label><addr-line>Department of Pathology, Weill Cornell Medical College, New York, New York, United States of America</addr-line></aff><aff id="aff003"><label>3</label><addr-line>Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York, United States of America</addr-line></aff><aff id="aff004"><label>4</label><addr-line>Weill Cornell Meyer Cancer Center, Weill Cornell Medical College, New York, New York, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Creighton</surname><given-names>Chad</given-names></name><role>Academic Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Baylor College of Medicine, UNITED STATES</addr-line></aff><author-notes><fn fn-type="conflict" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con" id="contrib001"><p>Conceived and designed the experiments: DRM LF DMN LJG. Performed the experiments: DRM LF QC. Analyzed the data: DRM LF QC. Contributed reagents/materials/analysis tools: QC SSG BDR DMN LJG. Wrote the paper: DRM LF QC SSG BDR DMN LJG.</p></fn><corresp id="cor001">* E-mail: <email>ljgudas@med.cornell.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>1</day><month>4</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>10</volume><issue>4</issue><elocation-id>e0120649</elocation-id><history><date date-type="received"><day>3</day><month>11</month><year>2014</year></date><date date-type="accepted"><day>25</day><month>1</month><year>2015</year></date></history><permissions><copyright-year>2015</copyright-year><copyright-holder>Minton et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="pone.0120649.pdf"/><abstract><p>Hypoxia inducible factor 1 alpha (HIF1&#x003b1;) is a transcription factor that is frequently stabilized and active in human clear cell renal cell carcinoma (ccRCC). We have found that constitutively active HIF1&#x003b1; is sufficient to cause neoplastic transformation in a murine model of ccRCC termed the TRACK model. RNA sequencing (RNAseq) and untargeted metabolomics analyses of samples from TRACK kidneys demonstrate that HIF1&#x003b1; activates the transcription of genes that cause increased glucose uptake, glycolysis, and lactate production, as well as a decrease in the flux of pyruvate entering the tricarboxylic acid (TCA) cycle and a decrease in oxidative phosphorylation; these changes are identical to those observed in human ccRCC samples. These studies show that a constitutively active HIF1&#x003b1; promotes tumorigenesis in TRACK mice by mediating a metabolic switch to aerobic glycolysis, i.e., the <italic>Warburg effect</italic>, and suggest that TRACK mice are a valid model to test novel therapies targeting metabolic changes to inhibit human ccRCC.</p></abstract><funding-group><funding-statement>This research was supported by WCMC, the Turobiner Kidney Cancer Research Fund, and the Genitourinary Oncology Research Fund. DRM was supported by the NIH T32 Training Grant (5T32CA062948). LF holds the Robert H. McCooey Genitourinary Oncology Research Fellowship and was supported in part by the NIH T32 Training Grant (CA062948). SSG was supported by NIH grants R37 HL087062 and PO1 HD067244. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="1"/><page-count count="14"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>TRACK RNA sequencing data are in the GEO database (accession no. GSE54390).</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>TRACK RNA sequencing data are in the GEO database (accession no. GSE54390).</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Each year, kidney cancer affects nearly 300,000 people and causes close to 100,000 deaths worldwide [<xref rid="pone.0120649.ref001" ref-type="bibr">1</xref>]. The majority of kidney cancer cases are clear cell renal cell carcinomas (ccRCCs), which are commonly linked to inactivating mutations of the von Hippel-Lindau tumor suppressor gene (<italic>VHL</italic>) [<xref rid="pone.0120649.ref002" ref-type="bibr">2</xref>]. The protein encoded by this gene, pVHL, regulates the activation of a family of transcription factors, hypoxia inducible factors (HIFs), that mediate the primary transcriptional responses to hypoxia in normal and neoplastic cells [<xref rid="pone.0120649.ref003" ref-type="bibr">3</xref>]. In ccRCC, pVHL inactivation results in aberrant regulation of HIF1&#x003b1;; this transcription factor accumulates, translocates to the nucleus, and binds to HIF1&#x003b2; [<xref rid="pone.0120649.ref003" ref-type="bibr">3</xref>,<xref rid="pone.0120649.ref004" ref-type="bibr">4</xref>]. This HIF1&#x003b1;/HIF1&#x003b2; dimer then binds to hypoxia response elements (HREs) on DNA to activate the transcription of target genes that are involved in angiogenesis, glucose uptake, enhanced glycolytic metabolism, and other processes related to cell proliferation [<xref rid="pone.0120649.ref003" ref-type="bibr">3</xref>,<xref rid="pone.0120649.ref004" ref-type="bibr">4</xref>].</p><p>While it is largely accepted that HIF1&#x003b1; is the more tumorigenic isoform in most types of cancer [<xref rid="pone.0120649.ref003" ref-type="bibr">3</xref>], some researchers have suggested that HIF2&#x003b1; is more tumorigenic than HIF1&#x003b1; in ccRCC [<xref rid="pone.0120649.ref005" ref-type="bibr">5</xref>]. One piece of data consistent with this idea is that HIF2&#x003b1; knockdown prevents the growth of tumors in a xenograft model, while HIF1&#x003b1; knockdown does not [<xref rid="pone.0120649.ref006" ref-type="bibr">6</xref>&#x02013;<xref rid="pone.0120649.ref008" ref-type="bibr">8</xref>]. However, these experiments do not assay for tumor development but rather for proliferation of tumor cells. An additional piece of data is that a loss of a portion of chromosome 14q near the location of <italic>HIF1&#x003b1;</italic> occurs frequently in ccRCC [<xref rid="pone.0120649.ref009" ref-type="bibr">9</xref>]. However, RNAseq data from The Cancer Genome Atlas Research Network show that <italic>HIF1&#x003b1;</italic> mRNA remains at a level within the range of that in tumors that are diploid for HIF1&#x003b1; in most ccRCC specimens that are affected by <italic>HIF1&#x003b1;</italic> loss of heterozygosity [<xref rid="pone.0120649.ref010" ref-type="bibr">10</xref>]. Consistent with these data, several groups have shown that HIF1&#x003b1; is highly expressed in a large number of ccRCC cases [<xref rid="pone.0120649.ref011" ref-type="bibr">11</xref>&#x02013;<xref rid="pone.0120649.ref013" ref-type="bibr">13</xref>], and that high HIF1&#x003b1; levels in tumors are associated with significantly lower patient survival [<xref rid="pone.0120649.ref014" ref-type="bibr">14</xref>]. Most recently, one group demonstrated expression of HIF1&#x003b1; by immunostaining in 84% of 106 primary surgical ccRCC specimens [<xref rid="pone.0120649.ref015" ref-type="bibr">15</xref>].</p><p>We previously reported that expression of a constitutively active form of HIF1&#x003b1; can drive tumorigenesis in a murine model of ccRCC called the TRACK (<bold>TRA</bold>nsgenic model of <bold>C</bold>ancer of the <bold>K</bold>idney) model [<xref rid="pone.0120649.ref016" ref-type="bibr">16</xref>]. TRACK mice express a mutated, constitutively active HIF1&#x003b1; that drives a program of tumorigenesis specifically in renal proximal tubules, and this tumorigenesis program mimics many features of early human ccRCC both phenotypically and at the molecular level [<xref rid="pone.0120649.ref016" ref-type="bibr">16</xref>]. TRACK kidney histologies display areas of distorted tubular structures, cells with clear cytoplasm and increased glycogen and lipid deposition, multiple renal cysts, and early onset of ccRCC [<xref rid="pone.0120649.ref016" ref-type="bibr">16</xref>]. These mice, however, do not develop metastases and the mice do not die prematurely. In contrast, we and others have shown that expression of a mutated, constitutively active HIF2&#x003b1; in the proximal tubules of mice does not result in neoplastic transformation and ccRCC [<xref rid="pone.0120649.ref017" ref-type="bibr">17</xref>,<xref rid="pone.0120649.ref018" ref-type="bibr">18</xref>]. The transgenic mice our lab generated that express constitutively active HIF2&#x003b1; in the proximal tubule cells develop glycogen deposits, but no tumors [<xref rid="pone.0120649.ref017" ref-type="bibr">17</xref>]. Collectively, these findings indicate that HIF1&#x003b1; plays a critical role in promoting renal tumorigenesis.</p><p>Altered tumor metabolism is now a widely accepted hallmark of cancer. Metabolic alterations accompany tumorigenesis and can be causal for tumor development and progression [<xref rid="pone.0120649.ref019" ref-type="bibr">19</xref>]. HIF1&#x003b1; is largely responsible for activating the transcription of target genes that drive various features of aberrant tumor metabolism, such as increased glucose uptake, increased glycolysis and lactate production, and decreased mitochondrial respiration [<xref rid="pone.0120649.ref020" ref-type="bibr">20</xref>,<xref rid="pone.0120649.ref021" ref-type="bibr">21</xref>]. Collectively, these features of tumor metabolism are commonly referred to as the <italic>Warburg effect</italic> [<xref rid="pone.0120649.ref022" ref-type="bibr">22</xref>]. The Warburg effect is a process in which cells rely on aerobic glycolysis instead of mitochondrial oxidative phosphorylation to generate energy, even though glycolysis is a less efficient pathway for producing ATP. Despite the relative bioenergetic cost of aerobic glycolysis, this shift in metabolism can confer an advantage by facilitating the generation of biomass needed to produce a new cell, and thus cancer cells acquire and metabolize nutrients in a manner that is conducive to proliferation rather than efficient ATP production [<xref rid="pone.0120649.ref022" ref-type="bibr">22</xref>].</p><p>Here we report that kidneys from TRACK mice exhibit increased expression of HIF1&#x003b1; target genes that have been linked to a shift in metabolism from mitochondrial oxidative phosphorylation to an accelerated rate of aerobic glycolysis and lactate production, similar to what is observed in human ccRCC. Additionally, we report metabolomics data and show that both the TRACK kidneys and human ccRCC samples exhibit increases in glycolytic intermediates and lactate, in association with a decrease in metabolites of the TCA cycle. Together, these data implicate HIF1&#x003b1; in mediating alterations in kidney metabolism that drive tumorigenesis, and suggest that TRACK mice represent a valid model to test therapies that target metabolism with the goal of inhibiting ccRCC.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Materials and Methods</title><sec id="sec003"><title>Samples</title><p>Male C57BL/6 mice (Jackson Laboratories) and TRACK mice were generated as described [<xref rid="pone.0120649.ref016" ref-type="bibr">16</xref>]. Three TRACK (TG<sup><bold>+</bold></sup>) and three wild-type littermates (TG<sup><bold>&#x02212;</bold></sup>) males, 18 months old, were selected for RNAseq analysis. Five TG<sup><bold>+</bold></sup> and five TG<sup><bold>&#x02212;</bold></sup> mice, 12 months old, were selected for metabolomics analyses. Older mice were selected for these experiments because they display a more advanced disease, which we hypothesized would more closely mimic features of human ccRCC. All procedures involving the use of mice were approved by the Weill Cornell Medical College (WCMC) Institutional Animal Use and Care Committee.</p><p>The WCMC Institutional Review Board (IRB) approved the use of human tissue samples for this study. A consent form is signed by all patients undergoing surgery, which states the tissue may be used for research purposes if tissue is collected and de-identified; the IRB approved this exemption/expedited protocol. ccRCC and adjacent normal kidney tissue samples were obtained from 12 patients who underwent radical or partial nephrectomy at WCMC. These samples were embedded in Optimal Cutting Medium (OCT), snap frozen, and stored at &#x02212;80&#x000b0;C. Hematoxylin and Eosin slides were prepared of the frozen tissue samples to ensure that the areas selected for metabolomics analysis represented either pure ccRCC or normal kidney tissue.</p></sec><sec id="sec004"><title>RNA Sequencing</title><p>High quality RNA was extracted from a thin layer of kidney cortex tissue (n = 6) using mini-RNAeasy columns (Qiagen) and RNAs were converted to cDNA by semi-quantitative reverse transcriptase (RT)-PCR. The WCMC Genomics Core performed the sequencing (51-bp single-end reads) on an Illumina HiSeq2000 Sequencer and data were analyzed as previously described [<xref rid="pone.0120649.ref017" ref-type="bibr">17</xref>]. In brief, data analysis was mainly performed with the Tuxedo tools software [<xref rid="pone.0120649.ref023" ref-type="bibr">23</xref>]. A stringent threshold was used to select differentially expressed genes (fold change &#x0003e;2 or &#x0003c;0.5, q&#x0003c;0.01). 655 genes showed increased mRNA levels and 55 genes showed decreased mRNA levels in TRACK TG+ kidney samples compared with the TG&#x02212; control kidney cortex samples. Data are in the GEO database (accession no. GSE54390).</p></sec><sec id="sec005"><title>Oncomine</title><p>The Oncomine Cancer Microarray database (<ext-link ext-link-type="uri" xlink:href="http://www.oncomine.org">http://www.oncomine.org</ext-link>) was used to study mRNA levels of genes most highly expressed in human ccRCC tumor types versus normal kidney tissue [<xref rid="pone.0120649.ref024" ref-type="bibr">24</xref>]. The data collected were from five different data sets [<xref rid="pone.0120649.ref025" ref-type="bibr">25</xref>&#x02013;<xref rid="pone.0120649.ref028" ref-type="bibr">28</xref>], each of which included data from 20&#x02013;260 patient samples. For our analysis, we searched for the genes most highly overexpressed in human ccRCC versus normal healthy renal tissue. Oncomine sorts overexpressed genes by &#x0201c;median rank,&#x0201d; which is the median p-value rank across data sets. For our purposes, we analyzed the top 30 ranked genes (<xref rid="pone.0120649.s002" ref-type="supplementary-material">S1 Table</xref>).</p></sec><sec id="sec006"><title>Metabolite Extraction</title><p>Mouse kidneys were isolated and snap-frozen in liquid nitrogen. Human tissue was embedded in OCT medium, snap frozen, and stored at &#x02212;80&#x000b0;C until the day of metabolite extraction. Tissue samples were washed twice with cold PBS, followed by bead-beating in 80% &#x02212;70&#x000b0;C methanol:water (LC-MS grade methanol, Fisher Scientific) using a Tissuelyser cell disrupter (Qiagen). The extraction mixture was incubated at 4&#x000b0;C for 10 min, and then centrifuged for 5 min at 13.2k rpm to separate the protein pellet. The extraction procedure was repeated twice. The supernatants were pooled, dried in a speed-vac (Savant) and stored at &#x02212;80&#x000b0;C. The pellets were solubilized in 200 &#x003bc;l of 0.2M NaOH by incubating at 95&#x000b0;C for 20 min, and protein contents were quantified with BioRad DC protein assays. Kidney metabolites were normalized to protein for LC/MS metabolomic analysis.</p></sec><sec id="sec007"><title>LC-MS and LC-MS/MS Platforms for Metabolite Profiling</title><p>The LC/MS and LC MS/MS instrumentation and setup were the same as described [<xref rid="pone.0120649.ref029" ref-type="bibr">29</xref>], except for the LC mobile phase composition and gradient. For the aqueous normal phase (ANP) separation, mobile phase A consisted of 0.025% acetic acid and 6 &#x003bc;M EDTA in 50% isopropanol: 50% ddH<sub>2</sub>O; mobile phase B consisted of 5 mM ammonium acetate and 6 &#x003bc;M EDTA in 90% acetonitrile (ACN). Gradient steps were: 0&#x02013;1 min, 99% B; 1&#x02013;15 min, to 0% B; 15&#x02013;29 min, 0% B; 29&#x02013;37 min, 99% B. The LC/MS data were acquired in both positive and negative ionization modes.</p></sec><sec id="sec008"><title>Metabolomics Data Processing and Statistical Analysis</title><p>Raw data files were processed by Agilent MassHunter Qualitative Analysis Software and analyzed by statistical analysis in Mass Profiler Professional (Agilent Technology, MPP, version B2.02) [<xref rid="pone.0120649.ref029" ref-type="bibr">29</xref>]. Aligned molecular features detected in all biological replicates of at least one group were directly applied for statistical analysis across treatment groups by MPP. The Benjamini Hochberg FDR correction was applied for multiple testing correction of p-values in one-way ANOVA (corrected p&#x0003c;0.05). An uncorrected p-value was used when individual metabolites were manually inspected for statistical significance between two groups (e.g. simple student t-test). Differential metabolites were identified using the METLIN Personal Metabolite Database (Agilent Technologies) and a molecular formula generator (MFG) algorithm in MPP as previously explained in detail [<xref rid="pone.0120649.ref030" ref-type="bibr">30</xref>].</p></sec></sec><sec sec-type="results" id="sec009"><title>Results</title><sec id="sec010"><title>Analysis of mRNA Expression in TRACK Kidneys and Human ccRCC Samples</title><p>We have previously shown that expression of a constitutively active, mutant form of HIF1&#x003b1; in the proximal tubules causes tumorigenesis in the TRACK mouse, a murine model of ccRCC [<xref rid="pone.0120649.ref016" ref-type="bibr">16</xref>]. These observations prompted us to delineate the genes that HIF1&#x003b1; activates in the TRACK mice. We performed RNAseq analyses on TRACK vs. wild type, transgenic negative (TG<sup><bold>&#x02212;</bold></sup>) kidney cortex samples and compared the results to mRNA expression data from Oncomine, a microarray database that compares gene expression in human cancers vs. normal tissue [<xref rid="pone.0120649.ref024" ref-type="bibr">24</xref>]. Specifically, we used this database to analyze results from five data sets of ccRCC, each of which included data from 20&#x02013;260 patients samples [<xref rid="pone.0120649.ref025" ref-type="bibr">25</xref>&#x02013;<xref rid="pone.0120649.ref028" ref-type="bibr">28</xref>]. For the purpose of this study, we focused on the top 30 overexpressed genes (ranked by median p-value rank across datasets) (<xref rid="pone.0120649.s002" ref-type="supplementary-material">S1 Table</xref>).</p><p>Many of the genes overexpressed in both human ccRCC and TRACK kidneys are implicated in altered tumor metabolism (<xref rid="pone.0120649.t001" ref-type="table">Table 1</xref>). Carbonic Anhydrase IX (CAIX, Gene ID: 768; mRNA increased 10-fold in TRACK mice and 16-fold in ccRCC) is a HIF1&#x003b1; target gene and a major biomarker of ccRCC [<xref rid="pone.0120649.ref031" ref-type="bibr">31</xref>,<xref rid="pone.0120649.ref032" ref-type="bibr">32</xref>]. It encodes a zinc metalloprotein anchored to the extracellular side of the plasma membrane and is believed to regulate extracellular pH for support of anaerobic tumor metabolism [<xref rid="pone.0120649.ref033" ref-type="bibr">33</xref>]. NADH dehydrogenase 1 alpha subcomplex, 4-like 2 (NDUFA4L2, Gene ID: 56901; mRNA increased &#x0003e;50-fold in both TRACK kidneys and ccRCC) is a subunit of complex 1 in the electron transport chain; upregulated by HIF1&#x003b1;, it inhibits oxidative phosphorylation and thus promotes the shift in metabolism to glycolysis [<xref rid="pone.0120649.ref034" ref-type="bibr">34</xref>]. Phosphofructokinase, platelet (PFKP, Gene ID: 5214; mRNA increased 10-fold in TRACK mice and 7-fold in ccRCC) encodes a kinase enzyme that catalyzes the conversion of fructose-6-phosphate to fructose-1,6-bisphosphate during the third step of glycolysis. This irreversible step in glycolysis is an important control point, and in tumors, PFKP plays a role in accelerating the rate of glycolysis [<xref rid="pone.0120649.ref035" ref-type="bibr">35</xref>,<xref rid="pone.0120649.ref036" ref-type="bibr">36</xref>]. Pyruvate dehydrogenase kinase, isoenzyme 1 (PDK1, Gene ID: 5163; mRNA increased 7.5-fold in TRACK kidneys and nearly 5-fold in ccRCC) phosphorylates and inactivates pyruvate dehydrogenase, an enzyme that converts pyruvate to acetyl-coenzyme A. Thus, PDK1 inhibits pyruvate metabolism via the TCA cycle and in turn inhibits oxidative phosphorylation [<xref rid="pone.0120649.ref037" ref-type="bibr">37</xref>]. Solute carrier family 2 (facilitated glucose transporter), member 1 (SLC2A1 or GLUT1, Gene ID 6513; mRNA increased 5-fold in TRACK kidneys and 2.5-fold in ccRCC) is not one of the top 30 ranked genes in human ccRCC according to Oncomine data, but SLC2A1 has been well studied in ccRCC and is known to play an important role in altered metabolism. More specifically, SLC2A1 is upregulated in cancers to accelerate the uptake of glucose and meet the energy needs of the tumor for an accelerated rate of glycolysis [<xref rid="pone.0120649.ref021" ref-type="bibr">21</xref>]. Lastly, solute carrier family 16, member 3 (SLC16A3 or MCT4, Gene ID: 9123; mRNA increased 87-fold in TRACK mice and nearly 7-fold in ccRCC) is a monocarboxylate transporter that is upregulated in many tumors because it is required for lactate secretion out of the cell, pH homeostasis, and maintenance of the Warburg effect [<xref rid="pone.0120649.ref038" ref-type="bibr">38</xref>]. With the exception of SLC2A1, which is a target gene of both a HIF1&#x003b1; and HIF2&#x003b1;, the other genes discussed are only regulated by HIF1&#x003b1; [<xref rid="pone.0120649.ref021" ref-type="bibr">21</xref>]. Thus, HIF1&#x003b1; is implicated in activating the transcription of genes associated with aerobic glycolysis in both the TRACK model of ccRCC and human ccRCC.</p><table-wrap id="pone.0120649.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0120649.t001</object-id><label>Table 1</label><caption><title>Comparison of TRACK kidney gene transcripts with human clear cell renal cell carcinoma.</title></caption><alternatives><graphic id="pone.0120649.t001g" xlink:href="pone.0120649.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Gene</th><th align="left" rowspan="1" colspan="1">Description</th><th align="left" rowspan="1" colspan="1">Fold Increase in ccRCC</th><th align="left" rowspan="1" colspan="1">Fold Increase in TRACK</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">CAIX</td><td align="left" rowspan="1" colspan="1">Carbonic Anhydrase IX</td><td align="left" rowspan="1" colspan="1">16.2</td><td align="left" rowspan="1" colspan="1">9.8</td></tr><tr><td align="left" rowspan="1" colspan="1">NDUFA4L2</td><td align="left" rowspan="1" colspan="1">NADH dehydrogenase 1 alpha subcomplex, 4-like 2</td><td align="left" rowspan="1" colspan="1">52.0</td><td align="left" rowspan="1" colspan="1">60.3</td></tr><tr><td align="left" rowspan="1" colspan="1">PDK1</td><td align="left" rowspan="1" colspan="1">Pyruvate dehydrogenase kinase, isoenzyme 1</td><td align="left" rowspan="1" colspan="1">7.0</td><td align="left" rowspan="1" colspan="1">7.5</td></tr><tr><td align="left" rowspan="1" colspan="1">PFKP</td><td align="left" rowspan="1" colspan="1">Phosphofructokinase, platelet</td><td align="left" rowspan="1" colspan="1">7.2</td><td align="left" rowspan="1" colspan="1">9.8</td></tr><tr><td align="left" rowspan="1" colspan="1">SLC2A1</td><td align="left" rowspan="1" colspan="1">Solute carrier family 2 (facilitated glucose transporter), member 1</td><td align="left" rowspan="1" colspan="1">2.5</td><td align="left" rowspan="1" colspan="1">4.7</td></tr><tr><td align="left" rowspan="1" colspan="1">SLC16A3</td><td align="left" rowspan="1" colspan="1">Solute carrier family 16, member 3</td><td align="left" rowspan="1" colspan="1">6.9</td><td align="left" rowspan="1" colspan="1">86.5</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>Selected genes that are most highly expressed in human ccRCC, and which show increased mRNA levels (fold change &#x0003e; 2) in the kidney tissue of the TRACK mice relative to kidneys from wild type littermates. Human data were collected from Oncomine, and TRACK data were obtained by RNAseq.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec011"><title>Untargeted Tissue Metabolite Profiling</title><p>We next performed metabolomic analyses on TRACK kidney samples to determine if the increases in mRNA levels observed for HIF1&#x003b1; target genes implicated in altered tumor metabolism are, in fact, associated with changes in metabolite levels in the TRACK kidneys. For comparison, we also extracted metabolites from primary human ccRCCs, along with adjacent normal kidney tissue as control. Principal component analysis (PCA) plots of the metabolomics data collected by both hydrophilic, aqueous normal phase chromatography with negative ion mode mass spectrometry (MS) detection (ANP-NEG) and positive ion mode MS detection (ANP-POS) show that the TG<sup><bold>&#x02212;</bold></sup> and TRACK samples are clearly distinguished, as are normal human kidney and ccRCC samples, which reflects distinct differences in the respective metabolomes (<xref rid="pone.0120649.s001" ref-type="supplementary-material">S1 Fig. A,B</xref>). Consistent with the unsupervised pattern recognition found by PCA, the hierarchical cluster analysis (HCA) dendogram similarly shows reproducible patterns of within-group similarity and between-group differences in the metabolites for each of the four groups analyzed (<xref rid="pone.0120649.s001" ref-type="supplementary-material">S1 Fig. C,D</xref>). Notably, for the human samples relative to mouse, tumors are genetically heterogeneous, explaining the greater metabolite variability for within-group similarities and between-group differences.</p></sec><sec id="sec012"><title>Analysis of Metabolic Changes in TRACK Kidneys</title><p>Prior studies have shown that in ccRCC, HIF1&#x003b1; upregulates expression of genes that mediate glucose uptake, SLC2A1 and SLC2A3, along with several glycolytic enzymes, including HK2, PFK-1, and LDHA, in accord with an oncogenic switch to aerobic glycolysis [<xref rid="pone.0120649.ref003" ref-type="bibr">3</xref>,<xref rid="pone.0120649.ref021" ref-type="bibr">21</xref>]. We therefore performed targeted inspection of the metabolite profiling data to assess whether lactate and glycolytic intermediates accumulate in TRACK kidneys. As illustrated in <xref rid="pone.0120649.g001" ref-type="fig">Fig. 1A</xref>, glucose levels are diminished, while pyruvate and lactate levels are significantly elevated, suggesting that the glycolytic and lactate production pathways are upregulated in TRACK kidneys (<xref rid="pone.0120649.g001" ref-type="fig">Fig. 1C</xref>).</p><fig id="pone.0120649.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0120649.g001</object-id><label>Fig 1</label><caption><title>Metabolomic analysis of key intermediates in glycolysis, lactate production, and the TCA cycle in TRACK kidneys.</title><p>A: Comparison of the levels of glycolysis and lactate production intermediates, glucose, pyruvate, and lactate in TG<sup><bold>&#x02212;</bold></sup> vs. TRACK kidney samples (n = 14 and 12). &#x025a1; = TG<sup><bold>&#x02212;</bold></sup>; <inline-formula id="pone.0120649.e001"><alternatives><graphic id="pone.0120649.e001g" xlink:href="pone.0120649.e001"/><mml:math id="M1"><mml:mi mathcolor="#A0A0A0">&#x025a0;</mml:mi></mml:math></alternatives></inline-formula> = TRACK. B: Comparison of the levels of fumarate, &#x003b1;-ketoglutarate, and citrate/isocitrate in WT vs. TRACK kidney samples (n = 14 and 12). &#x025a1; = TG<sup><bold>&#x02212;</bold></sup>; <inline-formula id="pone.0120649.e002"><alternatives><graphic id="pone.0120649.e002g" xlink:href="pone.0120649.e002"/><mml:math id="M2"><mml:mi mathcolor="#A0A0A0">&#x025a0;</mml:mi></mml:math></alternatives></inline-formula> = TRACK. C: Schematic overview of changes to glycolysis, lactate production, and the TCA cycle in TRACK kidneys. Error bars indicate the mean &#x000b1; SD. * indicates a p value &#x0003c;0.05, ** indicates a p value &#x0003c;0.01, and *** indicates a p value &#x0003c;0.001.</p></caption><graphic xlink:href="pone.0120649.g001"/></fig><p>Under (aerobic) conditions in most tissues pyruvate efficiently enters the TCA cycle and drives production of NADH, which fuels mitochondrial oxidative phosphorylation. However, in the setting of increased tissue lactate accumulation, as shown in the TRACK kidneys (<xref rid="pone.0120649.g001" ref-type="fig">Fig. 1A</xref>), we would expect to see a corresponding reduced flux of pyruvate entering the TCA cycle. In addition, our mRNA expression data showed that the HIF1&#x003b1; target, PDK1, a protein that is known to inhibit the TCA cycle [<xref rid="pone.0120649.ref037" ref-type="bibr">37</xref>], is increased in TRACK kidneys (<xref rid="pone.0120649.t001" ref-type="table">Table 1</xref>). Thus, we would predict a diminished level of TCA cycle activity and pathway intermediates in the TRACK kidney tumors. Metabolomics analysis indeed confirmed this hypothesis (<xref rid="pone.0120649.g001" ref-type="fig">Fig. 1B,C</xref>). Notably, we found that levels of key intermediates in the TCA cycle, fumarate and &#x003b1;-ketoglutarate, are lower in both the TRACK kidneys and human ccRCC samples (<xref rid="pone.0120649.g001" ref-type="fig">Fig. 1B</xref>). Taken together, the metabolomics and mRNA expression data indicate that TRACK kidney tumors exhibit glycolysis and lactate production and reduced flux of pyruvate entering the TCA cycle, which is in association with increased expression of HIF1&#x003b1; target genes that mediate the Warburg effect.</p><p>Alterations in cancer cell metabolism and energy production are adapted to facilitate the uptake and incorporation of nutrients into biomass, such as amino acids [<xref rid="pone.0120649.ref022" ref-type="bibr">22</xref>]. This is largely because of the high demand of cancer cells for macromolecular building blocks required for cell proliferation. We assessed TRACK kidney derived metabolites and found increased levels of multiple amino acids in the TRACK kidneys as compared to TG<sup><bold>&#x02212;</bold></sup> kidneys (<xref rid="pone.0120649.g002" ref-type="fig">Fig. 2A,B</xref>). Specifically, we detect significant increases in the levels of aspartate, methionine, valine, histidine, tyrosine, isoleucine, phenylalanine, and arginine (<xref rid="pone.0120649.g002" ref-type="fig">Fig. 2A,B</xref>). In addition to serving as precursors for protein synthesis, these amino acids can be metabolized to intermediates of the TCA cycle: &#x003b1;-ketoglutarate, succinate, fumarate, and oxaloacetate.</p><fig id="pone.0120649.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0120649.g002</object-id><label>Fig 2</label><caption><title>Metabolomic analysis of amino acid levels in TRACK kidneys.</title><p>A: Levels of amino acids in WT vs. TRACK mouse kidneys (n = 14 and 12). &#x025a1; = TG<sup><bold>&#x02212;</bold></sup>; <inline-formula id="pone.0120649.e003"><alternatives><graphic id="pone.0120649.e003g" xlink:href="pone.0120649.e003"/><mml:math id="M3"><mml:mi mathcolor="#A0A0A0">&#x025a0;</mml:mi></mml:math></alternatives></inline-formula> = TRACK. B: Schematic overview of changes to amino acid levels and TCA cycle. Error bars indicate the mean &#x000b1; SD. * indicates a p value &#x0003c;0.05, ** indicates a p value &#x0003c;0.01, and *** indicates a p value &#x0003c;0.001.</p></caption><graphic xlink:href="pone.0120649.g002"/></fig></sec><sec id="sec013"><title>Analysis of Metabolic Alterations in Human ccRCC Samples</title><p>Our hypothesis is that the TRACK model is representative of human ccRCC. When we compare the metabolomics analysis of TRACK kidneys to human ccRCC we detect higher levels of pyruvate and lactate in human ccRCCs, similar to what we detect in TRACK kidneys (<xref rid="pone.0120649.g003" ref-type="fig">Fig. 3A</xref>). As in the TRACK kidneys, after glucose is taken up in the ccRCC samples it is rapidly metabolized to pyruvate by glycolysis and then converted to lactate (<xref rid="pone.0120649.g003" ref-type="fig">Fig. 3A,C</xref>). Additionally, we found a reduction in TCA cycle intermediates in the ccRCC samples, including lower levels of fumarate and &#x003b1;-ketoglutarate (<xref rid="pone.0120649.g003" ref-type="fig">Fig. 3B</xref>). Overall, these changes are consistent with the view that both TRACK kidney and human ccRCC cells rely on anaerobic glycolysis instead of on the TCA cycle as a primary bioenergetics source for ATP production.</p><fig id="pone.0120649.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0120649.g003</object-id><label>Fig 3</label><caption><title>Metabolomic analysis of key intermediates in glycolysis, lactate production, and the TCA cycle in ccRCC samples.</title><p>A: Comparison of the levels of glycolysis and lactate production intermediates, glucose, pyruvate, and lactate in normal vs. ccRCC samples (n = 12). <inline-formula id="pone.0120649.e004"><alternatives><graphic id="pone.0120649.e004g" xlink:href="pone.0120649.e004"/><mml:math id="M4"><mml:mi mathcolor="#A0A0A0">&#x025a0;</mml:mi></mml:math></alternatives></inline-formula> = Normal; &#x025a0; = ccRCC. B: Comparison of the levels of fumarate, &#x003b1;-ketoglutarate, and citrate/isocitrate in normal vs. ccRCC samples (n = 12). <inline-formula id="pone.0120649.e005"><alternatives><graphic id="pone.0120649.e005g" xlink:href="pone.0120649.e005"/><mml:math id="M5"><mml:mi mathcolor="#A0A0A0">&#x025a0;</mml:mi></mml:math></alternatives></inline-formula> = Normal; &#x025a0; = ccRCC. C: Schematic overview of changes to glycolysis, lactate production, and the TCA cycle in ccRCC. Error bars indicate the mean &#x000b1; SD. * indicates a p value &#x0003c;0.05, ** indicates a p value &#x0003c;0.01, and *** indicates a p value &#x0003c;0.001.</p></caption><graphic xlink:href="pone.0120649.g003"/></fig><p>In the ccRCC samples, we also observe increased levels of the TCA cycle intermediate(s) citrate/isocitrate (these cannot be differentiated by metabolomic analysis) (<xref rid="pone.0120649.g003" ref-type="fig">Fig. 3B</xref>), while there were no changes in the levels of these intermediates in the TRACK model (<xref rid="pone.0120649.g001" ref-type="fig">Fig. 1A</xref>) Additionally, and in contrast to our findings in the TRACK kidneys, we did not detect changes to the levels of various amino acids in the ccRCC samples (data not shown).</p></sec></sec><sec sec-type="conclusions" id="sec014"><title>Discussion</title><p>In this study we have demonstrated that TRACK mice exhibit altered tumor metabolism that is highly similar to the changes detected in human ccRCC samples. Our data from RNA sequencing and the Oncomine database indicate that many HIF1&#x003b1; target genes that mediate glucose uptake and glycolysis, suppress the activity of the TCA cycle and mitochondrial respiration, and maintain pH homeostasis during aerobic respiration show increased transcript levels in TRACK mice (<xref rid="pone.0120649.t001" ref-type="table">Table 1</xref>). These results are not surprising, since TRACK mice selectively express a mutant, constitutively active form of HIF1&#x003b1; in the renal proximal tubules where these transcriptome changes are observed [<xref rid="pone.0120649.ref016" ref-type="bibr">16</xref>].</p><p>In agreement with these results on mRNA expression, analysis of the metabolome further demonstrates that HIF1&#x003b1; mediates altered metabolism in TRACK kidneys (Figs. <xref rid="pone.0120649.g001" ref-type="fig">1</xref>&#x02013;<xref rid="pone.0120649.g002" ref-type="fig">2</xref>). We found that pyruvate and lactate levels are increased in TRACK kidneys, in accord with an increase in glycolysis and lactate production (<xref rid="pone.0120649.g001" ref-type="fig">Fig. 1A,C</xref>). Additionally, reduced levels of &#x003b1;-ketoglutarate and fumarate, metabolites of the TCA cycle, are seen in the TRACK kidneys, suggestive of a reduced flux of pyruvate entering the TCA cycle (<xref rid="pone.0120649.g001" ref-type="fig">Fig. 1B,C</xref>). Since the TCA cycle is responsible for generating NADH to fuel mitochondrial oxidative phosphorylation, we also infer that oxidative phosphorylation is reduced in TRACK kidneys. The mRNA expression data corroborate this inference, since we detect higher levels of NDUFA4L2, a known inhibitor of oxidative phosphorylation, in TRACK kidney samples (<xref rid="pone.0120649.t001" ref-type="table">Table 1</xref>). Previous studies have also shown that HIF1&#x003b1; inhibits mitochondrial biogenesis and reduces oxygen consumption in VHL-null renal cell carcinoma [<xref rid="pone.0120649.ref039" ref-type="bibr">39</xref>], which is consistent with our findings. Furthermore, a decrease in SIRT6 expression leads to HIF1&#x003b1; activation that results in increased glucose uptake, with upregulation of glycolysis and diminished mitochondrial respiration [<xref rid="pone.0120649.ref040" ref-type="bibr">40</xref>]. Overall, our data suggest that HIF1&#x003b1; mediates the shift from mitochondrial respiration to glycolysis in TRACK kidneys.</p><p>It has long been known that cancer cells acquire and metabolize nutrients in a manner that is conducive to proliferation rather than efficient ATP production [<xref rid="pone.0120649.ref022" ref-type="bibr">22</xref>]. The synthesis of new proteins is required for the enhanced proliferation of cancer cells. In TRACK kidneys we detect increases in the levels of many different amino acids that are required for protein synthesis (<xref rid="pone.0120649.g002" ref-type="fig">Fig. 2A,B</xref>). Amino acid uptake has not been well studied in human ccRCC. However, one study has shown that reduced expression of PDK1 by 75&#x02013;90% in a hypomorphic murine model leads to a reduction in renal absorption of amino acids [<xref rid="pone.0120649.ref041" ref-type="bibr">41</xref>]. This is likely because these mice have decreased expression of various amino acid transporters in the proximal tubule cells [<xref rid="pone.0120649.ref041" ref-type="bibr">41</xref>]. We show that PDK1 is a HIF1&#x003b1; target gene that is highly expressed at the mRNA level in TRACK kidneys (and human ccRCC samples), and that there are increased levels of amino acids in the TRACK kidneys (<xref rid="pone.0120649.g002" ref-type="fig">Fig. 2A,B</xref>). Together, these data suggest a link between HIF1&#x003b1; activation and amino acid uptake. Further studies will be needed to determine if HIF1&#x003b1; mediated expression of PDK1 leads to an increase in amino acid uptake in human ccRCC.</p><p>Notably, many of the changes to metabolite levels in TRACK kidneys are similar to the changes observed in human ccRCC samples. In human ccRCC samples, we also detect an increase in pyruvate and lactate, and a decrease in TCA cycle metabolites &#x003b1;-ketoglutarate and fumarate (<xref rid="pone.0120649.g003" ref-type="fig">Fig. 3A,B</xref>). Thus, in both TRACK kidneys and human ccRCC samples we observe increases in glycolysis and lactate production and a reduced flux of pyruvate entering the TCA cycle (Figs. <xref rid="pone.0120649.g001" ref-type="fig">1</xref> and <xref rid="pone.0120649.g003" ref-type="fig">3</xref>). These findings suggest that constitutively active HIF1&#x003b1; is sufficient to mediate altered tumor metabolism in TRACK kidneys and likely contributes to the altered metabolism in human ccRCC.</p><p>Some of the changes in metabolite levels were dissimilar in the TRACK kidneys and human ccRCC samples. To start, we did not observe an increase in the level(s) of citrate/isocitrate in TRACK kidneys (<xref rid="pone.0120649.g001" ref-type="fig">Fig. 1B</xref>) like we did in the human ccRCC samples (<xref rid="pone.0120649.g003" ref-type="fig">Fig. 3B,C</xref>). Hypoxia is sufficient to reduce intracellular citrate levels, which in turn induces the anapleurotic process of reductive glutamine metabolism to fuel lipid biosynthesis for rapid cell proliferation [<xref rid="pone.0120649.ref042" ref-type="bibr">42</xref>,<xref rid="pone.0120649.ref043" ref-type="bibr">43</xref>]. In our study, the levels of citrate/isocitrate are trending towards lower in the TRACK kidneys (<xref rid="pone.0120649.g001" ref-type="fig">Fig. 1B</xref>), which is in agreement with the data in the literature that high HIF1&#x003b1; expression is sufficient to induce reductive glutamine metabolism [<xref rid="pone.0120649.ref042" ref-type="bibr">42</xref>,<xref rid="pone.0120649.ref044" ref-type="bibr">44</xref>]. However, in ccRCC tumor cells are dependent on reductive glutamine metabolism for lipid biosynthesis [<xref rid="pone.0120649.ref042" ref-type="bibr">42</xref>,<xref rid="pone.0120649.ref044" ref-type="bibr">44</xref>] and thus it is surprising that we detected elevated levels of citrate/isocitrate in ccRCC tumors compared to those in normal kidney tissue (<xref rid="pone.0120649.g003" ref-type="fig">Fig. 3B,C</xref>). Additional differences in the TRACK kidneys compared to human ccRCC samples are the changes in amino acids levels. Many amino acids are elevated in TRACK kidney samples (<xref rid="pone.0120649.g002" ref-type="fig">Fig. 2A,B</xref>) but there are no changes in these amino acids in ccRCC samples (data not shown). One potential explanation for this difference is that the stages of tumorigenesis in the TRACK kidneys vs. the human ccRCC samples are different. Notably, the human tumor samples are from a more advanced stage of tumorigenesis than the TRACK samples.</p><p>Altered tumor metabolism is now a widely accepted hallmark of cancer, and metabolic alterations greatly influence tumor development and progression [<xref rid="pone.0120649.ref019" ref-type="bibr">19</xref>]. We have shown that HIF1&#x003b1; increases transcripts that encode proteins that mediate increased glycolysis, increased lactate production, and decreased mitochondrial respiration in TRACK kidneys. Additionally, our metabolomics analyses further demonstrate that HIF1&#x003b1; mediates altered tumor metabolism in TRACK kidneys, which is highly similar to the changes observed in human ccRCC. It was previously suggested that HIF1&#x003b1; mediates the Warburg effect in human ccRCC, though these earlier data were based on measurements of transcripts alone, without establishing the activities of encoded proteins [<xref rid="pone.0120649.ref045" ref-type="bibr">45</xref>]. Our analyses of the metabolome expand on this prior knowledge and establish the ability of HIF1&#x003b1; to mediate altered tumor metabolism in an informative renal cancer model, the TRACK mouse. Additionally, these data show that the TRACK model is a highly relevant model of metabolic ccRCC that can be utilized for testing novel therapies that target altered tumor metabolism to inhibit ccRCC.</p></sec><sec sec-type="supplementary-material" id="sec015"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0120649.s001"><label>S1 Fig</label><caption><title>Untargeted metabolomic profiling of WT vs. TRACK mouse kidneys, and normal vs. tumor human kidneys.</title><p>A: Principal component analysis plot of ANP-NEG data showing a three dimensional visualization of similarities and differences between each samples. B: Principal component analysis clustering of ANP-POS data showing a three dimensional visualization of similarities and differences between each sample. C: Unsupervised hierarchical cluster analysis of ANP-NEG data based on the Pearson correlation. D: Unsupervised hierarchical cluster analysis of ANP-POS data based on the Pearson correlation.</p><p>(TIF)</p></caption><media xlink:href="pone.0120649.s001.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0120649.s002"><label>S1 Table</label><caption><title>Overexpressed Genes in Human ccRCC.</title><p>Data from Oncomine, a cancer microarray database that collects data to compare mRNA levels in human cancer vs. normal tissue. The data were collected from five datasets, each of which collected data from 20&#x02013;260 patient samples. The rank for each gene is the median rank for that gene across each of the analyses, and the p-value for each gene is its p-value for the median-ranked analysis. The fold change for each gene is listed from each dataset: 1. Hereditary ccRCC, Beroukhim, et al. (2009). 2. Non-Hereditary ccRCC, Beroukhim, et al. (2009). 3. Gumz, et al. (2007). 4. Lenburg, et al. (2003). 5. Yusenko, et al. (2009). The median fold change is the median fold change calculated from the 5 datasets.</p><p>(DOCX)</p></caption><media xlink:href="pone.0120649.s002.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We thank Sagit Goldenberg for assistance in obtaining human ccRCC tissue samples, Dr. Campagne for help with GobyWeb, Dr. Tuo Zhang for help with the RNAseq data, and members of the Gudas, Nanus, and Gross laboratories for advice.</p></ack><ref-list><title>References</title><ref id="pone.0120649.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Ricketts</surname><given-names>CJ</given-names></name>, <name><surname>Linehan</surname><given-names>WM</given-names></name>. <article-title>Intratumoral heterogeneity in kidney cancer</article-title>. <source>Nat Genet</source>. <year>2014</year>;<volume>46</volume>(<issue>3</issue>):<fpage>214</fpage>&#x02013;<lpage>5</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ng.2904">10.1038/ng.2904</ext-link></comment><?supplied-pmid 24569233?><pub-id pub-id-type="pmid">24569233</pub-id></mixed-citation></ref><ref id="pone.0120649.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Shuin</surname><given-names>T</given-names></name>, <name><surname>Kondo</surname><given-names>K</given-names></name>, <name><surname>Torigoe</surname><given-names>S</given-names></name>, <name><surname>Kishida</surname><given-names>T</given-names></name>, <name><surname>Kubota</surname><given-names>Y</given-names></name>, <name><surname>Hosaka</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas</article-title>. <source>Cancer Res</source>. <year>1994</year>;<volume>54</volume>(<issue>11</issue>):<fpage>2852</fpage>&#x02013;<lpage>5</lpage>. <?supplied-pmid 8187067?><pub-id pub-id-type="pmid">8187067</pub-id></mixed-citation></ref><ref id="pone.0120649.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Semenza</surname><given-names>GL</given-names></name>. <article-title>Targeting HIF-1 for cancer therapy</article-title>. <source>Nat Rev Cancer</source>. <year>2003</year>;<volume>3</volume>(<issue>10</issue>):<fpage>721</fpage>&#x02013;<lpage>32</lpage>. <?supplied-pmid 13130303?><pub-id pub-id-type="pmid">13130303</pub-id></mixed-citation></ref><ref id="pone.0120649.ref004"><label>4</label><mixed-citation publication-type="other">Gudas LJ, Fu L, Minton DR, Mongan NP, Nanus DM. The role of HIF1&#x003b1; in renal cell carcinoma tumorigenesis. J Mol Med (Berl). 2014.</mixed-citation></ref><ref id="pone.0120649.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Gordan</surname><given-names>JD</given-names></name>, <name><surname>Simon</surname><given-names>MC</given-names></name>. <article-title>Hypoxia-inducible factors: central regulators of the tumor phenotype</article-title>. <source>Curr Opin Genet Dev</source>. <year>2007</year>;<volume>17</volume>(<issue>1</issue>):<fpage>71</fpage>&#x02013;<lpage>7</lpage>. <?supplied-pmid 17208433?><pub-id pub-id-type="pmid">17208433</pub-id></mixed-citation></ref><ref id="pone.0120649.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Zimmer</surname><given-names>M</given-names></name>, <name><surname>Doucette</surname><given-names>D</given-names></name>, <name><surname>Siddiqui</surname><given-names>N</given-names></name>, <name><surname>Iliopoulos</surname><given-names>O</given-names></name>. <article-title>Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors</article-title>. <source>Mol Cancer Res</source>. <year>2004</year>;<volume>2</volume>(<issue>2</issue>):<fpage>89</fpage>&#x02013;<lpage>95</lpage>. <?supplied-pmid 14985465?><pub-id pub-id-type="pmid">14985465</pub-id></mixed-citation></ref><ref id="pone.0120649.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Maranchie</surname><given-names>JK</given-names></name>, <name><surname>Vasselli</surname><given-names>JR</given-names></name>, <name><surname>Riss</surname><given-names>J</given-names></name>, <name><surname>Bonifacino</surname><given-names>JS</given-names></name>, <name><surname>Linehan</surname><given-names>WM</given-names></name>, <name><surname>Klausner</surname><given-names>RD</given-names></name>. <article-title>The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma</article-title>. <source>Cancer Cell</source>. <year>2002</year>;<volume>1</volume>(<issue>3</issue>):<fpage>247</fpage>&#x02013;<lpage>55</lpage>. <?supplied-pmid 12086861?><pub-id pub-id-type="pmid">12086861</pub-id></mixed-citation></ref><ref id="pone.0120649.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Kondo</surname><given-names>K</given-names></name>, <name><surname>Klco</surname><given-names>J</given-names></name>, <name><surname>Nakamura</surname><given-names>E</given-names></name>, <name><surname>Lechpammer</surname><given-names>M</given-names></name>, <name><surname>Kaelin</surname><given-names>WG</given-names></name>. <article-title>Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein</article-title>. <source>Cancer Cell</source>. <year>2002</year>;<volume>1</volume>(<issue>3</issue>):<fpage>237</fpage>&#x02013;<lpage>46</lpage>. <?supplied-pmid 12086860?><pub-id pub-id-type="pmid">12086860</pub-id></mixed-citation></ref><ref id="pone.0120649.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Shen</surname><given-names>C</given-names></name>, <name><surname>Beroukhim</surname><given-names>R</given-names></name>, <name><surname>Schumacher</surname><given-names>SE</given-names></name>, <name><surname>Zhou</surname><given-names>J</given-names></name>, <name><surname>Chang</surname><given-names>M</given-names></name>, <name><surname>Signoretti</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Genetic and functional studies implicate HIF1&#x003b1; as a 14q kidney cancer suppressor gene</article-title>. <source>Cancer Discov</source>. <year>2011</year>;<volume>1</volume>(<issue>3</issue>):<fpage>222</fpage>&#x02013;<lpage>35</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/2159-8290.CD-11-0098">10.1158/2159-8290.CD-11-0098</ext-link></comment>
<?supplied-pmid 22037472?><pub-id pub-id-type="pmid">22037472</pub-id></mixed-citation></ref><ref id="pone.0120649.ref010"><label>10</label><mixed-citation publication-type="journal"><collab>Network CGAR</collab>. <article-title>Comprehensive molecular characterization of clear cell renal cell carcinoma</article-title>. <source>Nature</source>. <year>2013</year>;<volume>499</volume>(<issue>7456</issue>):<fpage>43</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature12222">10.1038/nature12222</ext-link></comment>
<?supplied-pmid 23792563?><pub-id pub-id-type="pmid">23792563</pub-id></mixed-citation></ref><ref id="pone.0120649.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Gordan</surname><given-names>JD</given-names></name>, <name><surname>Lal</surname><given-names>P</given-names></name>, <name><surname>Dondeti</surname><given-names>VR</given-names></name>, <name><surname>Letrero</surname><given-names>R</given-names></name>, <name><surname>Parekh</surname><given-names>KN</given-names></name>, <name><surname>Oquendo</surname><given-names>CE</given-names></name>, <etal>et al</etal>
<article-title>HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma</article-title>. <source>Cancer Cell</source>. <year>2008</year>;<volume>14</volume>(<issue>6</issue>):<fpage>435</fpage>&#x02013;<lpage>46</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ccr.2008.10.016">10.1016/j.ccr.2008.10.016</ext-link></comment>
<?supplied-pmid 19061835?><pub-id pub-id-type="pmid">19061835</pub-id></mixed-citation></ref><ref id="pone.0120649.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Chintala</surname><given-names>S</given-names></name>, <name><surname>Najrana</surname><given-names>T</given-names></name>, <name><surname>Toth</surname><given-names>K</given-names></name>, <name><surname>Cao</surname><given-names>S</given-names></name>, <name><surname>Durrani</surname><given-names>FA</given-names></name>, <name><surname>Pili</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition</article-title>. <source>BMC Cancer</source>. <year>2012</year>;<volume>12</volume>:<fpage>293</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1471-2407-12-293">10.1186/1471-2407-12-293</ext-link></comment>
<?supplied-pmid 22804960?><pub-id pub-id-type="pmid">22804960</pub-id></mixed-citation></ref><ref id="pone.0120649.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Schultz</surname><given-names>L</given-names></name>, <name><surname>Chaux</surname><given-names>A</given-names></name>, <name><surname>Albadine</surname><given-names>R</given-names></name>, <name><surname>Hicks</surname><given-names>J</given-names></name>, <name><surname>Kim</surname><given-names>JJ</given-names></name>, <name><surname>De Marzo</surname><given-names>AM</given-names></name>, <etal>et al</etal>
<article-title>Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas</article-title>. <source>Am J Surg Pathol</source>. <year>2011</year>;<volume>35</volume>(<issue>10</issue>):<fpage>1549</fpage>&#x02013;<lpage>56</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/PAS.0b013e31822895e5">10.1097/PAS.0b013e31822895e5</ext-link></comment>
<?supplied-pmid 21881486?><pub-id pub-id-type="pmid">21881486</pub-id></mixed-citation></ref><ref id="pone.0120649.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Klatte</surname><given-names>T</given-names></name>, <name><surname>Seligson</surname><given-names>DB</given-names></name>, <name><surname>Riggs</surname><given-names>SB</given-names></name>, <name><surname>Leppert</surname><given-names>JT</given-names></name>, <name><surname>Berkman</surname><given-names>MK</given-names></name>, <name><surname>Kleid</surname><given-names>MD</given-names></name>, <etal>et al</etal>
<article-title>Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma</article-title>. <source>Clin Cancer Res</source>. <year>2007</year>;<volume>13</volume>(<issue>24</issue>):<fpage>7388</fpage>&#x02013;<lpage>93</lpage>. <?supplied-pmid 18094421?><pub-id pub-id-type="pmid">18094421</pub-id></mixed-citation></ref><ref id="pone.0120649.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Sato</surname><given-names>Y</given-names></name>, <name><surname>Yoshizato</surname><given-names>T</given-names></name>, <name><surname>Shiraishi</surname><given-names>Y</given-names></name>, <name><surname>Maekawa</surname><given-names>S</given-names></name>, <name><surname>Okuno</surname><given-names>Y</given-names></name>, <name><surname>Kamura</surname><given-names>T</given-names></name>, <etal>et al</etal>
<article-title>Integrated molecular analysis of clear-cell renal cell carcinoma</article-title>. <source>Nat Genet</source>. <year>2013</year>;<volume>45</volume>(<issue>8</issue>):<fpage>860</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ng.2699">10.1038/ng.2699</ext-link></comment>
<?supplied-pmid 23797736?><pub-id pub-id-type="pmid">23797736</pub-id></mixed-citation></ref><ref id="pone.0120649.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Fu</surname><given-names>L</given-names></name>, <name><surname>Wang</surname><given-names>G</given-names></name>, <name><surname>Shevchuk</surname><given-names>MM</given-names></name>, <name><surname>Nanus</surname><given-names>DM</given-names></name>, <name><surname>Gudas</surname><given-names>LJ</given-names></name>. <article-title>Generation of a mouse model of Von Hippel-Lindau kidney disease leading to renal cancers by expression of a constitutively active mutant of HIF1&#x003b1;</article-title>. <source>Cancer Res</source>. <year>2011</year>;<volume>71</volume>(<issue>21</issue>):<fpage>6848</fpage>&#x02013;<lpage>56</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/0008-5472.CAN-11-1745">10.1158/0008-5472.CAN-11-1745</ext-link></comment>
<?supplied-pmid 21908555?><pub-id pub-id-type="pmid">21908555</pub-id></mixed-citation></ref><ref id="pone.0120649.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Fu</surname><given-names>L</given-names></name>, <name><surname>Wang</surname><given-names>G</given-names></name>, <name><surname>Shevchuk</surname><given-names>MM</given-names></name>, <name><surname>Nanus</surname><given-names>DM</given-names></name>, <name><surname>Gudas</surname><given-names>LJ</given-names></name>. <article-title>Activation of HIF2&#x003b1; in Kidney Proximal Tubule Cells Causes Abnormal Glycogen Deposition but not Tumorigenesis</article-title>. <source>Cancer Res</source>. <year>2013</year>;<volume>73</volume>(<issue>9</issue>):<fpage>2916</fpage>&#x02013;<lpage>25</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/0008-5472.CAN-12-3983">10.1158/0008-5472.CAN-12-3983</ext-link></comment>
<?supplied-pmid 23447580?><pub-id pub-id-type="pmid">23447580</pub-id></mixed-citation></ref><ref id="pone.0120649.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Schietke</surname><given-names>RE</given-names></name>, <name><surname>Hackenbeck</surname><given-names>T</given-names></name>, <name><surname>Tran</surname><given-names>M</given-names></name>, <name><surname>G&#x000fc;nther</surname><given-names>R</given-names></name>, <name><surname>Klanke</surname><given-names>B</given-names></name>, <name><surname>Warnecke</surname><given-names>CL</given-names></name>, <etal>et al</etal>
<article-title>Renal tubular HIF-2&#x003b1; expression requires VHL inactivation and causes fibrosis and cysts</article-title>. <source>PLoS One</source>. <year>2012</year>;<volume>7</volume>(<issue>1</issue>):<fpage>e31034</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0031034">10.1371/journal.pone.0031034</ext-link></comment>
<?supplied-pmid 22299048?><pub-id pub-id-type="pmid">22299048</pub-id></mixed-citation></ref><ref id="pone.0120649.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Jones</surname><given-names>RG</given-names></name>, <name><surname>Thompson</surname><given-names>CB</given-names></name>. <article-title>Tumor suppressors and cell metabolism: a recipe for cancer growth</article-title>. <source>Genes Dev</source>. <year>2009</year>;<volume>23</volume>(<issue>5</issue>):<fpage>537</fpage>&#x02013;<lpage>48</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1101/gad.1756509">10.1101/gad.1756509</ext-link></comment>
<?supplied-pmid 19270154?><pub-id pub-id-type="pmid">19270154</pub-id></mixed-citation></ref><ref id="pone.0120649.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Chiavarina</surname><given-names>B</given-names></name>, <name><surname>Martinez-Outschoorn</surname><given-names>UE</given-names></name>, <name><surname>Whitaker-Menezes</surname><given-names>D</given-names></name>, <name><surname>Howell</surname><given-names>A</given-names></name>, <name><surname>Tanowitz</surname><given-names>HB</given-names></name>, <name><surname>Pestell</surname><given-names>RG</given-names></name>, <etal>et al</etal>
<article-title>Metabolic reprogramming and two-compartment tumor metabolism: opposing role(s) of HIF1&#x003b1; and HIF2&#x003b1; in tumor-associated fibroblasts and human breast cancer cells</article-title>. <source>Cell Cycle</source>. <year>2012</year>;<volume>11</volume>(<issue>17</issue>):<fpage>3280</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.4161/cc.21643">10.4161/cc.21643</ext-link></comment>
<?supplied-pmid 22894905?><pub-id pub-id-type="pmid">22894905</pub-id></mixed-citation></ref><ref id="pone.0120649.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Keith</surname><given-names>B</given-names></name>, <name><surname>Johnson</surname><given-names>RS</given-names></name>, <name><surname>Simon</surname><given-names>MC</given-names></name>. <article-title>HIF1&#x003b1; and HIF2&#x003b1;: sibling rivalry in hypoxic tumour growth and progression</article-title>. <source>Nat Rev Cancer</source>. <year>2012</year>;<volume>12</volume>(<issue>1</issue>):<fpage>9</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="pmid">22169972</pub-id></mixed-citation></ref><ref id="pone.0120649.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Vander Heiden</surname><given-names>MG</given-names></name>, <name><surname>Cantley</surname><given-names>LC</given-names></name>, <name><surname>Thompson</surname><given-names>CB</given-names></name>. <article-title>Understanding the Warburg effect: the metabolic requirements of cell proliferation</article-title>. <source>Science</source>. <year>2009</year>;<volume>324</volume>(<issue>5930</issue>):<fpage>1029</fpage>&#x02013;<lpage>33</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1126/science.1160809">10.1126/science.1160809</ext-link></comment>
<?supplied-pmid 19460998?><pub-id pub-id-type="pmid">19460998</pub-id></mixed-citation></ref><ref id="pone.0120649.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Trapnell</surname><given-names>C</given-names></name>, <name><surname>Roberts</surname><given-names>A</given-names></name>, <name><surname>Goff</surname><given-names>L</given-names></name>, <name><surname>Pertea</surname><given-names>G</given-names></name>, <name><surname>Kim</surname><given-names>D</given-names></name>, <name><surname>Kelley</surname><given-names>DR</given-names></name>, <etal>et al</etal>
<article-title>Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks</article-title>. <source>Nat Protoc</source>. <year>2012</year>;<volume>7</volume>(<issue>3</issue>):<fpage>562</fpage>&#x02013;<lpage>78</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nprot.2012.016">10.1038/nprot.2012.016</ext-link></comment>
<?supplied-pmid 22383036?><pub-id pub-id-type="pmid">22383036</pub-id></mixed-citation></ref><ref id="pone.0120649.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Rhodes</surname><given-names>DR</given-names></name>, <name><surname>Yu</surname><given-names>J</given-names></name>, <name><surname>Shanker</surname><given-names>K</given-names></name>, <name><surname>Deshpande</surname><given-names>N</given-names></name>, <name><surname>Varambally</surname><given-names>R</given-names></name>, <name><surname>Ghosh</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>ONCOMINE: a cancer microarray database and integrated data-mining platform</article-title>. <source>Neoplasia</source>. <year>2004</year>;<volume>6</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>6</lpage>. <?supplied-pmid 15068665?><pub-id pub-id-type="pmid">15068665</pub-id></mixed-citation></ref><ref id="pone.0120649.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Beroukhim</surname><given-names>R</given-names></name>, <name><surname>Brunet</surname><given-names>JP</given-names></name>, <name><surname>Di Napoli</surname><given-names>A</given-names></name>, <name><surname>Mertz</surname><given-names>KD</given-names></name>, <name><surname>Seeley</surname><given-names>A</given-names></name>, <name><surname>Pires</surname><given-names>MM</given-names></name>, <etal>et al</etal>
<article-title>Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney</article-title>. <source>Cancer Res</source>. <year>2009</year>;<volume>69</volume>(<issue>11</issue>):<fpage>4674</fpage>&#x02013;<lpage>81</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/0008-5472.CAN-09-0146">10.1158/0008-5472.CAN-09-0146</ext-link></comment>
<?supplied-pmid 19470766?><pub-id pub-id-type="pmid">19470766</pub-id></mixed-citation></ref><ref id="pone.0120649.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Gumz</surname><given-names>ML</given-names></name>, <name><surname>Zou</surname><given-names>H</given-names></name>, <name><surname>Kreinest</surname><given-names>PA</given-names></name>, <name><surname>Childs</surname><given-names>AC</given-names></name>, <name><surname>Belmonte</surname><given-names>LS</given-names></name>, <name><surname>LeGrand</surname><given-names>SN</given-names></name>, <etal>et al</etal>
<article-title>Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma</article-title>. <source>Clin Cancer Res</source>. <year>2007</year>;<volume>13</volume>(<issue>16</issue>):<fpage>4740</fpage>&#x02013;<lpage>9</lpage>. <?supplied-pmid 17699851?><pub-id pub-id-type="pmid">17699851</pub-id></mixed-citation></ref><ref id="pone.0120649.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Lenburg</surname><given-names>ME</given-names></name>, <name><surname>Liou</surname><given-names>LS</given-names></name>, <name><surname>Gerry</surname><given-names>NP</given-names></name>, <name><surname>Frampton</surname><given-names>GM</given-names></name>, <name><surname>Cohen</surname><given-names>HT</given-names></name>, <name><surname>Christman</surname><given-names>MF</given-names></name>. <article-title>Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data</article-title>. <source>BMC Cancer</source>. <year>2003</year>;<volume>3</volume>:<fpage>31</fpage>
<?supplied-pmid 14641932?><pub-id pub-id-type="pmid">14641932</pub-id></mixed-citation></ref><ref id="pone.0120649.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Yusenko</surname><given-names>MV</given-names></name>, <name><surname>Kuiper</surname><given-names>RP</given-names></name>, <name><surname>Boethe</surname><given-names>T</given-names></name>, <name><surname>Ljungberg</surname><given-names>B</given-names></name>, <name><surname>van Kessel</surname><given-names>AG</given-names></name>, <name><surname>Kovacs</surname><given-names>G</given-names></name>. <article-title>High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas</article-title>. <source>BMC Cancer</source>. <year>2009</year>;<volume>9</volume>:<fpage>152</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1471-2407-9-152">10.1186/1471-2407-9-152</ext-link></comment>
<?supplied-pmid 19445733?><pub-id pub-id-type="pmid">19445733</pub-id></mixed-citation></ref><ref id="pone.0120649.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>Q</given-names></name>, <name><surname>Park</surname><given-names>HC</given-names></name>, <name><surname>Goligorsky</surname><given-names>MS</given-names></name>, <name><surname>Chander</surname><given-names>P</given-names></name>, <name><surname>Fischer</surname><given-names>SM</given-names></name>, <name><surname>Gross</surname><given-names>SS</given-names></name>. <article-title>Untargeted plasma metabolite profiling reveals the broad systemic consequences of xanthine oxidoreductase inactivation in mice</article-title>. <source>PLoS One</source>. <year>2012</year>;<volume>7</volume>(<issue>6</issue>):<fpage>e37149</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0037149">10.1371/journal.pone.0037149</ext-link></comment>
<?supplied-pmid 22723833?><pub-id pub-id-type="pmid">22723833</pub-id></mixed-citation></ref><ref id="pone.0120649.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Gao</surname><given-names>J</given-names></name>, <name><surname>Aksoy</surname><given-names>BA</given-names></name>, <name><surname>Dogrusoz</surname><given-names>U</given-names></name>, <name><surname>Dresdner</surname><given-names>G</given-names></name>, <name><surname>Gross</surname><given-names>B</given-names></name>, <name><surname>Sumer</surname><given-names>SO</given-names></name>, <etal>et al</etal>
<article-title>Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal</article-title>. <source>Sci Signal</source>. <year>2013</year>;<volume>6</volume>(<issue>269</issue>):pl1. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1126/scisignal.2003345">10.1126/scisignal.2003345</ext-link></comment>
<?supplied-pmid 23550212?><pub-id pub-id-type="pmid">23550212</pub-id></mixed-citation></ref><ref id="pone.0120649.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Bui</surname><given-names>MH</given-names></name>, <name><surname>Seligson</surname><given-names>D</given-names></name>, <name><surname>Han</surname><given-names>KR</given-names></name>, <name><surname>Pantuck</surname><given-names>AJ</given-names></name>, <name><surname>Dorey</surname><given-names>FJ</given-names></name>, <name><surname>Huang</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy</article-title>. <source>Clin Cancer Res</source>. <year>2003</year>;<volume>9</volume>(<issue>2</issue>):<fpage>802</fpage>&#x02013;<lpage>11</lpage>. <?supplied-pmid 12576453?><pub-id pub-id-type="pmid">12576453</pub-id></mixed-citation></ref><ref id="pone.0120649.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Sandlund</surname><given-names>J</given-names></name>, <name><surname>Oosterwijk</surname><given-names>E</given-names></name>, <name><surname>Grankvist</surname><given-names>K</given-names></name>, <name><surname>Oosterwijk-Wakka</surname><given-names>J</given-names></name>, <name><surname>Ljungberg</surname><given-names>B</given-names></name>, <name><surname>Rasmuson</surname><given-names>T</given-names></name>. <article-title>Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma</article-title>. <source>BJU Int</source>. <year>2007</year>;<volume>100</volume>(<issue>3</issue>):<fpage>556</fpage>&#x02013;<lpage>60</lpage>. <?supplied-pmid 17608827?><pub-id pub-id-type="pmid">17608827</pub-id></mixed-citation></ref><ref id="pone.0120649.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Robertson</surname><given-names>N</given-names></name>, <name><surname>Potter</surname><given-names>C</given-names></name>, <name><surname>Harris</surname><given-names>AL</given-names></name>. <article-title>Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion</article-title>. <source>Cancer Res</source>. <year>2004</year>;<volume>64</volume>(<issue>17</issue>):<fpage>6160</fpage>&#x02013;<lpage>5</lpage>. <?supplied-pmid 15342400?><pub-id pub-id-type="pmid">15342400</pub-id></mixed-citation></ref><ref id="pone.0120649.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Tello</surname><given-names>D</given-names></name>, <name><surname>Balsa</surname><given-names>E</given-names></name>, <name><surname>Acosta-Iborra</surname><given-names>B</given-names></name>, <name><surname>Fuertes-Yebra</surname><given-names>E</given-names></name>, <name><surname>Elorza</surname><given-names>A</given-names></name>, <name><surname>Ord&#x000f3;&#x000f1;ez</surname><given-names>&#x000c1;</given-names></name>, <etal>et al</etal>
<article-title>Induction of the mitochondrial NDUFA4L2 protein by HIF-1&#x003b1; decreases oxygen consumption by inhibiting Complex I activity</article-title>. <source>Cell Metab</source>. <year>2011</year>;<volume>14</volume>(<issue>6</issue>):<fpage>768</fpage>&#x02013;<lpage>79</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cmet.2011.10.008">10.1016/j.cmet.2011.10.008</ext-link></comment>
<?supplied-pmid 22100406?><pub-id pub-id-type="pmid">22100406</pub-id></mixed-citation></ref><ref id="pone.0120649.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Yalcin</surname><given-names>A</given-names></name>, <name><surname>Telang</surname><given-names>S</given-names></name>, <name><surname>Clem</surname><given-names>B</given-names></name>, <name><surname>Chesney</surname><given-names>J</given-names></name>. <article-title>Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer</article-title>. <source>Exp Mol Pathol</source>. <year>2009</year>;<volume>86</volume>(<issue>3</issue>):<fpage>174</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.yexmp.2009.01.003">10.1016/j.yexmp.2009.01.003</ext-link></comment>
<?supplied-pmid 19454274?><pub-id pub-id-type="pmid">19454274</pub-id></mixed-citation></ref><ref id="pone.0120649.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Mor</surname><given-names>I</given-names></name>, <name><surname>Cheung</surname><given-names>EC</given-names></name>, <name><surname>Vousden</surname><given-names>KH</given-names></name>. <article-title>Control of glycolysis through regulation of PFK1: old friends and recent additions</article-title>. <source>Cold Spring Harb Symp Quant Biol</source>. <year>2011</year>;<volume>76</volume>:<fpage>211</fpage>&#x02013;<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1101/sqb.2011.76.010868">10.1101/sqb.2011.76.010868</ext-link></comment>
<?supplied-pmid 22096029?><pub-id pub-id-type="pmid">22096029</pub-id></mixed-citation></ref><ref id="pone.0120649.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>JW</given-names></name>, <name><surname>Tchernyshyov</surname><given-names>I</given-names></name>, <name><surname>Semenza</surname><given-names>GL</given-names></name>, <name><surname>Dang</surname><given-names>CV</given-names></name>. <article-title>HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia</article-title>. <source>Cell Metab</source>. <year>2006</year>;<volume>3</volume>(<issue>3</issue>):<fpage>177</fpage>&#x02013;<lpage>85</lpage>. <?supplied-pmid 16517405?><pub-id pub-id-type="pmid">16517405</pub-id></mixed-citation></ref><ref id="pone.0120649.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Gerlinger</surname><given-names>M</given-names></name>, <name><surname>Santos</surname><given-names>CR</given-names></name>, <name><surname>Spencer-Dene</surname><given-names>B</given-names></name>, <name><surname>Martinez</surname><given-names>P</given-names></name>, <name><surname>Endesfelder</surname><given-names>D</given-names></name>, <name><surname>Burrell</surname><given-names>RA</given-names></name>, <etal>et al</etal>
<article-title>Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target</article-title>. <source>J Pathol</source>. <year>2012</year>;<volume>227</volume>(<issue>2</issue>):<fpage>146</fpage>&#x02013;<lpage>56</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/path.4006">10.1002/path.4006</ext-link></comment>
<?supplied-pmid 22362593?><pub-id pub-id-type="pmid">22362593</pub-id></mixed-citation></ref><ref id="pone.0120649.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>H</given-names></name>, <name><surname>Gao</surname><given-names>P</given-names></name>, <name><surname>Fukuda</surname><given-names>R</given-names></name>, <name><surname>Kumar</surname><given-names>G</given-names></name>, <name><surname>Krishnamachary</surname><given-names>B</given-names></name>, <name><surname>Zeller</surname><given-names>KI</given-names></name>, <etal>et al</etal>
<article-title>HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity</article-title>. <source>Cancer Cell</source>. <year>2007</year>;<volume>11</volume>(<issue>5</issue>):<fpage>407</fpage>&#x02013;<lpage>20</lpage>. <?supplied-pmid 17482131?><pub-id pub-id-type="pmid">17482131</pub-id></mixed-citation></ref><ref id="pone.0120649.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Zhong</surname><given-names>L</given-names></name>, <name><surname>D'Urso</surname><given-names>A</given-names></name>, <name><surname>Toiber</surname><given-names>D</given-names></name>, <name><surname>Sebastian</surname><given-names>C</given-names></name>, <name><surname>Henry</surname><given-names>RE</given-names></name>, <name><surname>Vadysirisack</surname><given-names>DD</given-names></name>, <etal>et al</etal>
<article-title>The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha</article-title>. <source>Cell</source>. <year>2010</year>;<volume>140</volume>(<issue>2</issue>):<fpage>280</fpage>&#x02013;<lpage>93</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2009.12.041">10.1016/j.cell.2009.12.041</ext-link></comment>
<?supplied-pmid 20141841?><pub-id pub-id-type="pmid">20141841</pub-id></mixed-citation></ref><ref id="pone.0120649.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Rexhepaj</surname><given-names>R</given-names></name>, <name><surname>Grahammer</surname><given-names>F</given-names></name>, <name><surname>V&#x000f6;lkl</surname><given-names>H</given-names></name>, <name><surname>Remy</surname><given-names>C</given-names></name>, <name><surname>Wagner</surname><given-names>CA</given-names></name>, <name><surname>Sandulache</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>Reduced intestinal and renal amino acid transport in PDK1 hypomorphic mice</article-title>. <source>FASEB J</source>. <year>2006</year>;<volume>20</volume>(<issue>13</issue>):<fpage>2214</fpage>&#x02013;<lpage>22</lpage>. <?supplied-pmid 17077298?><pub-id pub-id-type="pmid">17077298</pub-id></mixed-citation></ref><ref id="pone.0120649.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Metallo</surname><given-names>CM</given-names></name>, <name><surname>Gameiro</surname><given-names>PA</given-names></name>, <name><surname>Bell</surname><given-names>EL</given-names></name>, <name><surname>Mattaini</surname><given-names>KR</given-names></name>, <name><surname>Yang</surname><given-names>J</given-names></name>, <name><surname>Hiller</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia</article-title>. <source>Nature</source>. <year>2012</year>;<volume>481</volume>(<issue>7381</issue>):<fpage>380</fpage>&#x02013;<lpage>4</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature10602">10.1038/nature10602</ext-link></comment>
<?supplied-pmid 22101433?><pub-id pub-id-type="pmid">22101433</pub-id></mixed-citation></ref><ref id="pone.0120649.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Wise</surname><given-names>DR</given-names></name>, <name><surname>Ward</surname><given-names>PS</given-names></name>, <name><surname>Shay</surname><given-names>JE</given-names></name>, <name><surname>Cross</surname><given-names>JR</given-names></name>, <name><surname>Gruber</surname><given-names>JJ</given-names></name>, <name><surname>Sachdeva</surname><given-names>UM</given-names></name>, <etal>et al</etal>
<article-title>Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of &#x003b1;-ketoglutarate to citrate to support cell growth and viability</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2011</year>;<volume>108</volume>(<issue>49</issue>):<fpage>19611</fpage>&#x02013;<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.1117773108">10.1073/pnas.1117773108</ext-link></comment>
<?supplied-pmid 22106302?><pub-id pub-id-type="pmid">22106302</pub-id></mixed-citation></ref><ref id="pone.0120649.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Gameiro</surname><given-names>PA</given-names></name>, <name><surname>Yang</surname><given-names>J</given-names></name>, <name><surname>Metelo</surname><given-names>AM</given-names></name>, <name><surname>P&#x000e9;rez-Carro</surname><given-names>R</given-names></name>, <name><surname>Baker</surname><given-names>R</given-names></name>, <name><surname>Wang</surname><given-names>Z</given-names></name>, <etal>et al</etal>
<article-title>In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation</article-title>. <source>Cell Metab</source>. <year>2013</year>;<volume>17</volume>(<issue>3</issue>):<fpage>372</fpage>&#x02013;<lpage>85</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cmet.2013.02.002">10.1016/j.cmet.2013.02.002</ext-link></comment>
<?supplied-pmid 23473032?><pub-id pub-id-type="pmid">23473032</pub-id></mixed-citation></ref><ref id="pone.0120649.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Semenza</surname><given-names>GL</given-names></name>. <article-title>HIF-1 mediates the Warburg effect in clear cell renal carcinoma</article-title>. <source>J Bioenerg Biomembr</source>. <year>2007</year>;<volume>39</volume>(<issue>3</issue>):<fpage>231</fpage>&#x02013;<lpage>4</lpage>. <?supplied-pmid 17551816?><pub-id pub-id-type="pmid">17551816</pub-id></mixed-citation></ref></ref-list></back></article>